<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39467851</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1432-8798</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Archives of virology</Title><ISOAbbreviation>Arch Virol</ISOAbbreviation></Journal><ArticleTitle>Prim-O-glucosylcimifugin alleviates influenza virus-induced pneumonia in mice by inhibiting the TGF-β1/PI3KCD/MSK2/RELA signalling pathway.</ArticleTitle><Pagination><StartPage>232</StartPage><MedlinePgn>232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00705-024-06158-5</ELocationID><Abstract><AbstractText>Prim-O-glucosylcimifugin (POG) is a chromone derived primarily from Saposhnikovia divaricata (Turcz) Schischk and Cimicifuga simplex. Previous research has shown that POG possesses antibacterial, anticancer, anti-inflammatory, antioxidant, anticonvulsant, antipyretic, and analgesic properties. However, the specific impact of POG on influenza-virus-induced pneumonia is not well understood. In this study, we investigated the protective effects and underlying mechanisms of POG in pneumonia caused by influenza A virus (IAV). In vitro, POG was found to have a protective effect against infections caused by the respiratory viruses respiratory syncytial virus (RSV), human coronavirus OC43, and influenza A virus. POG inhibited A/FM/1/1947(H1N1) infection with an EC<sub>50</sub> ranging from 3.01 to 10.43 in vitro. Intraperitoneal infection of mice with POG at a dose of 5 or 10 mg/kg resulted in a reduction in IAV-induced pneumonia, as evidenced by decreased pulmonary edema, improved lung histopathology, and reduced inflammatory cell accumulation. At the higher dose (10 mg/kg), POG treatment significantly increased survival rates, decreased viral titres in the lungs, improved lung histology, and reduced lung inflammation in IAV-infected mice. POG also effectively alleviated pulmonary fibrosis by reducing the levels of fibrotic markers (hydroxyproline [Hyp] and transforming growth factor β1 [TGF-β1]) and suppressing the expression of alpha smooth muscle actin (α-SMA), p focal adhesion kinase (p-FAK), and TGF-β1 in lung tissues. In addition, POG inhibited the expression of the RELA proto-oncogene (RELA), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (PIK3CD), and mitogen- and stress-activated protein kinase 2 (MSK2) in lung tissues. These results indicate that POG may have a protective effect against IAV-induced pneumonia by downregulating the TGF-β1/PI3KCD/MSK2/RELA signalling pathway in the lungs.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu-Jia</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist, Guangzhou, Guangdong, 510405, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Wen-Wen</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist, Guangzhou, Guangdong, 510405, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhen-Lin</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist, Guangzhou, Guangdong, 510405, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yue-Yao</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist, Guangzhou, Guangdong, 510405, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jin-Yuan</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Basic Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Pei-Ping</ForeName><Initials>PP</Initials><Identifier Source="ORCID">0000-0002-6720-7327</Identifier><AffiliationInfo><Affiliation>Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, 12 Jichang Rd., San Yuanli St., Bai Yun Dist, Guangzhou, Guangdong, 510405, People's Republic of China. xupeiping@gzucm.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82141208</GrantID><Agency>Key Programme</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Arch Virol</MedlineTA><NlmUniqueID>7506870</NlmUniqueID><ISSNLinking>0304-8608</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051996">Transcription Factor RelA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002867">Chromones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053773" MajorTopicYN="Y">Transforming Growth Factor beta1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="Y">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051996" MajorTopicYN="N">Transcription Factor RelA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061985" MajorTopicYN="N">Madin Darby Canine Kidney Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-inflammatory activity</Keyword><Keyword MajorTopicYN="N">Influenza A virus</Keyword><Keyword MajorTopicYN="N">Prim-O-glucosylcimifugin</Keyword><Keyword MajorTopicYN="N">Viral pneumonia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39467851</ArticleId><ArticleId IdType="doi">10.1007/s00705-024-06158-5</ArticleId><ArticleId IdType="pii">10.1007/s00705-024-06158-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS (2002) Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360(9348):1831–1837</Citation><ArticleIdList><ArticleId IdType="pubmed">12480361</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(02)11772-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrickson CM, Matthay MA (2013) Viral pathogens and acute lung injury: investigations inspired by the SARS epidemic and the 2009 H1N1 influenza pandemic. Semin Respir Crit Care Med 34(4):475–486</Citation><ArticleIdList><ArticleId IdType="pubmed">23934716</ArticleId><ArticleId IdType="pmc">4045622</ArticleId><ArticleId IdType="doi">10.1055/s-0033-1351122</ArticleId></ArticleIdList></Reference><Reference><Citation>Denholm JT, Gordon CL, Johnson PD, Hewagama SS, Stuart RL, Aboltins C, Jeremiah C, Knox J, Lane GP, Tramontana AR et al (2010) Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Australia 192(2):84–86</Citation><ArticleIdList><ArticleId IdType="pubmed">20078408</ArticleId><ArticleId IdType="doi">10.5694/j.1326-5377.2010.tb03424.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM (2008) H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 4(8):e1000115</Citation><ArticleIdList><ArticleId IdType="pubmed">18670648</ArticleId><ArticleId IdType="pmc">2483250</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1000115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M (2017) Drug resistance in influenza A virus: the epidemiology and management. Infect drug Resist 10:121–134</Citation><ArticleIdList><ArticleId IdType="pubmed">28458567</ArticleId><ArticleId IdType="pmc">5404498</ArticleId><ArticleId IdType="doi">10.2147/IDR.S105473</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang RJ, Min ZH, Xu CY (1988) [Pharmacologic studies on the root of Saposhnikovia divaricata (Turcz.) Schischk]. Zhong Yao Tong Bao 13(6):44–46</Citation><ArticleIdList><ArticleId IdType="pubmed">3264523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Liu X, Lu X, Huang C (2017) Prim-O-glucosylcimifugin induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells. Anticancer Drugs 28(9):943–951</Citation><ArticleIdList><ArticleId IdType="pubmed">28692435</ArticleId><ArticleId IdType="doi">10.1097/CAD.0000000000000543</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Wu Q, Chi G, Soromou LW, Hou J, Deng Y, Feng H (2013) Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol 16(2):139–147</Citation><ArticleIdList><ArticleId IdType="pubmed">23623941</ArticleId><ArticleId IdType="pmc">7106058</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2013.04.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LQ, Li Y, Li YY, Xu SH, Yang ZY, Lin Z, Li J (2016) Antinociceptive Effects of Prim-O-Glucosylcimifugin in Inflammatory Nociception via Reducing Spinal COX-2. Biomolecules Ther 24(4):418–425</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2015.168</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Liu K, Li G (2022) Protective Effect of Prim-O-Glucosylcimifugin on Ulcerative Colitis and Its Mechanism. Front Pharmacol 13:882924</Citation><ArticleIdList><ArticleId IdType="pubmed">35662727</ArticleId><ArticleId IdType="pmc">9158503</ArticleId><ArticleId IdType="doi">10.3389/fphar.2022.882924</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao W, Zhang X, Yang W, Dou D, Zhang H, Tang Y, Zhong W, Meng J, Bai Y, Liu Y et al (2019) Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells. J Immunother Cancer 7(1):231</Citation><ArticleIdList><ArticleId IdType="pubmed">31462297</ArticleId><ArticleId IdType="pmc">6714432</ArticleId><ArticleId IdType="doi">10.1186/s40425-019-0676-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Yang XB, Yang XW, Liu JX (2012) Biotransformation of prim-O-glucosylcimifugin by human intestinal flora and its inhibition on NO production and DPPH free radical. J Asian Nat Prod Res 14(9):886–896</Citation><ArticleIdList><ArticleId IdType="pubmed">22917273</ArticleId><ArticleId IdType="doi">10.1080/10286020.2012.702756</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao SH, Li Y, Lai YN, Liu N, Zhang FX, Xu PP (2017) Ribavirin attenuates the respiratory immune responses to influenza viral infection in mice. Arch Virol 162(6):1661–1669</Citation><ArticleIdList><ArticleId IdType="pubmed">28243801</ArticleId><ArticleId IdType="doi">10.1007/s00705-017-3291-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping O, Ruixue Y, Jiaqiang D, Kaiyu W, Jing F, Yi G, Xiaoli H, Defang C, Weimin L, Li T et al (2018) Subinhibitory Concentrations of Prim-O-Glucosylcimifugin Decrease the Expression of Alpha-Hemolysin in Staphylococcus aureus (USA300). Evidence-based complementary and alternative medicine: eCAM 2018:7579808</Citation></Reference><Reference><Citation>Zhou J, Sun YY, Sun MY, Mao WA, Wang L, Zhang J, Zhang H (2017) Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages. Pharmacogn Mag 13(51):378–384</Citation><ArticleIdList><ArticleId IdType="pubmed">28839360</ArticleId><ArticleId IdType="pmc">5551353</ArticleId><ArticleId IdType="doi">10.4103/pm.pm_323_16</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, Chan RW, Long HT, Poon LL, Guan Y et al (2005) Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 6(1):135</Citation><ArticleIdList><ArticleId IdType="pubmed">16283933</ArticleId><ArticleId IdType="pmc">1318487</ArticleId><ArticleId IdType="doi">10.1186/1465-9921-6-135</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe W, Sudo K, Asawa S, Konno K, Yokota T, Shigeta S (1995) Use of lactate dehydrogenase to evaluate the anti-viral activity against influenza A virus. J Virol Methods 51(2–3):185–191</Citation><ArticleIdList><ArticleId IdType="pubmed">7738138</ArticleId><ArticleId IdType="doi">10.1016/0166-0934(94)00103-N</ArticleId></ArticleIdList></Reference><Reference><Citation>Spackman E, Malladi S, Ssematimba A, Stephens CB (2019) Assessment of replicate numbers for titrating avian influenza virus using dose-response models. J veterinary Diagn investigation: official publication Am Association Veterinary Lab Diagnosticians Inc 31(4):616–619</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1040638719853851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HX, Zeng MS, Ye Y, Liu JY, Xu PP (2021) Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase. Phytother Res 35(1):324–336</Citation><ArticleIdList><ArticleId IdType="pubmed">32757226</ArticleId><ArticleId IdType="doi">10.1002/ptr.6803</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lai YN, Wang Y, Liu N, Zhang FX, Xu PP (2016) 1, 8-Cineol Protect Against Influenza-Virus-Induced Pneumonia in Mice. Inflammation 39(4):1582–1593</Citation><ArticleIdList><ArticleId IdType="pubmed">27351430</ArticleId><ArticleId IdType="doi">10.1007/s10753-016-0394-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Zeng M, Xu P, Liu J, Wang H (2021) Effect of paeoniflorin on acute lung injury induced by influenza A virus in mice. Evidences of its mechanism of action. Phytomedicine 92:153724</Citation><ArticleIdList><ArticleId IdType="pubmed">34509953</ArticleId><ArticleId IdType="doi">10.1016/j.phymed.2021.153724</ArticleId></ArticleIdList></Reference><Reference><Citation>Korteweg C, Gu JA (2010) Pandemic influenza A (H1N1) virus infection and avian influenza A (H5N1) virus infection: a comparative analysis. Biochem Cell Biol 88(4):575–587</Citation><ArticleIdList><ArticleId IdType="pubmed">20651828</ArticleId><ArticleId IdType="doi">10.1139/O10-017</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG (2006) Antiviral resistance in influenza viruses - Implications for management and pandemic response. New Engl J Med 354(8):785–788</Citation><ArticleIdList><ArticleId IdType="pubmed">16495389</ArticleId><ArticleId IdType="doi">10.1056/NEJMp068030</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z, Chen Z, Li X, Xu L, Guan W, Cao Y, Hu Y, Zhang J (2014) Host immunological response and factors associated with clinical outcome in patients with the novel influenza A H7N9 infection. Clin Microbiol infection: official publication Eur Soc Clin Microbiol Infect Dis 20(8):O493–500</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngamsri KC, Wagner R, Vollmer I, Stark S, Reutershan J (2010) Adenosine receptor A1 regulates polymorphonuclear cell trafficking and microvascular permeability in lipopolysaccharide-induced lung injury. J Immunol 185(7):4374–4384</Citation><ArticleIdList><ArticleId IdType="pubmed">20729330</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1000433</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia CC, Tavares LP, Dias ACF, Kehdy F, Alvarado-Arnez LE, Queiroz-Junior CM, Galvao I, Lima BH, Matos AR, Goncalves APF et al (2018) Phosphatidyl Inositol 3 Kinase-Gamma Balances Antiviral and Inflammatory Responses During Influenza A H1N1 Infection: From Murine Model to Genetic Association in Patients. Front Immunol 9:975</Citation><ArticleIdList><ArticleId IdType="pubmed">29867955</ArticleId><ArticleId IdType="pmc">5962662</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.00975</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiscott J, Kwon H, Genin P (2001) Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Investig 107(2):143–151</Citation><ArticleIdList><ArticleId IdType="pubmed">11160127</ArticleId><ArticleId IdType="pmc">199181</ArticleId><ArticleId IdType="doi">10.1172/JCI11918</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig S, Planz O, Pleschka S, Wolff T (2003) Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Mol Med 9(2):46–52</Citation><ArticleIdList><ArticleId IdType="pubmed">12615037</ArticleId><ArticleId IdType="doi">10.1016/S1471-4914(02)00010-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuh K, Pahl A (2009) Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury. Biochem Pharmacol 77(12):1827–1834</Citation><ArticleIdList><ArticleId IdType="pubmed">19428337</ArticleId><ArticleId IdType="doi">10.1016/j.bcp.2009.03.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Li G, Guo W, Zhang J (2020) The protective effect and mechanism of pedunculoside on DSS (dextran sulfate sodium) induced ulcerative colitis in mice. Int Immunopharmacol 88:107017</Citation><ArticleIdList><ArticleId IdType="pubmed">33182072</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2020.107017</ArticleId></ArticleIdList></Reference><Reference><Citation>Nennig SE, Schank JR (2017) The Role of NFkB in Drug Addiction: Beyond Inflammation. Alcohol Alcohol 52(2):172–179</Citation><ArticleIdList><ArticleId IdType="pubmed">28043969</ArticleId><ArticleId IdType="pmc">6410896</ArticleId><ArticleId IdType="doi">10.1093/alcalc/agw098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee FS, Hagler J, Chen ZJ, Maniatis T (1997) Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88(2):213–222</Citation><ArticleIdList><ArticleId IdType="pubmed">9008162</ArticleId><ArticleId IdType="doi">10.1016/S0092-8674(00)81842-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LF, Mu Y, Greene WC (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21(23):6539–6548</Citation><ArticleIdList><ArticleId IdType="pubmed">12456660</ArticleId><ArticleId IdType="pmc">136963</ArticleId><ArticleId IdType="doi">10.1093/emboj/cdf660</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H, Wang H, Ma L, Ma X, Yin J, Wu S, Huang H, Li Y (2018) Cirsimaritin inhibits influenza A virus replication by downregulating the NF-kappaB signal transduction pathway. Virol J 15(1):88</Citation><ArticleIdList><ArticleId IdType="pubmed">29783993</ArticleId><ArticleId IdType="pmc">5963025</ArticleId><ArticleId IdType="doi">10.1186/s12985-018-0995-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauge C, Frodin M (2006) RSK and MSK in MAP kinase signalling. J Cell Sci 119(Pt 15):3021–3023</Citation><ArticleIdList><ArticleId IdType="pubmed">16868029</ArticleId><ArticleId IdType="doi">10.1242/jcs.02950</ArticleId></ArticleIdList></Reference><Reference><Citation>Deak M, Clifton AD, Lucocq LM, Alessi DR (1998) Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 17(15):4426–4441</Citation><ArticleIdList><ArticleId IdType="pubmed">9687510</ArticleId><ArticleId IdType="pmc">1170775</ArticleId><ArticleId IdType="doi">10.1093/emboj/17.15.4426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS (2002) MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22(8):2871–2881</Citation><ArticleIdList><ArticleId IdType="pubmed">11909979</ArticleId><ArticleId IdType="pmc">133730</ArticleId><ArticleId IdType="doi">10.1128/MCB.22.8.2871-2881.2002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakugawa S, Shimojima M, Goto H, Horimoto T, Oshimori N, Neumann G, Yamamoto T, Kawaoka Y (2009) Mitogen-activated protein kinase-activated kinase RSK2 plays a role in innate immune responses to influenza virus infection. J Virol 83(6):2510–2517</Citation><ArticleIdList><ArticleId IdType="pubmed">19129453</ArticleId><ArticleId IdType="pmc">2648281</ArticleId><ArticleId IdType="doi">10.1128/JVI.02416-08</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SH, Zhao GY, Liu CF, Wu XH, Guo Y, Yu H, Song HB, Du LY, Jiang SB, Guo RF et al (2013) Inhibition of Complement Activation Alleviates Acute Lung Injury Induced by Highly Pathogenic Avian Influenza H5N1 Virus Infection. Am J Resp Cell Mol 49(2):221–230</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2012-0428OC</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakab GJ, Hemenway DR (1992) Experimental influenza virus infection, silicon dioxide polymorphs, and pulmonary fibrogenesis. J Toxicol Environ Health 37(1):11–24</Citation><ArticleIdList><ArticleId IdType="pubmed">1326056</ArticleId><ArticleId IdType="doi">10.1080/15287399209531653</ArticleId></ArticleIdList></Reference><Reference><Citation>Passos IC, Vasconcelos-Moreno MP, Costa LG, Kunz M, Brietzke E, Quevedo J, Salum G, Magalhaes PV, Kapczinski F, Kauer-Sant'Anna M (2015) Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. lancet Psychiatry 2(11):1002–1012</Citation><ArticleIdList><ArticleId IdType="pubmed">26544749</ArticleId><ArticleId IdType="doi">10.1016/S2215-0366(15)00309-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly L, Stavrou A, Vanderstoken G, Meliopoulos VA, Habgood A, Tatler AL, Porte J, Knox A, Weinreb P, Violette S et al (2014) Influenza promotes collagen deposition via alphavbeta6 integrin-mediated transforming growth factor beta activation. J Biol Chem 289(51):35246–35263</Citation><ArticleIdList><ArticleId IdType="pubmed">25339175</ArticleId><ArticleId IdType="pmc">4271213</ArticleId><ArticleId IdType="doi">10.1074/jbc.M114.582262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheaton AK, Agarwal M, Jia S, Kim KK (2017) Lung epithelial cell focal adhesion kinase signaling inhibits lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 312(5):L722–L730</Citation><ArticleIdList><ArticleId IdType="pubmed">28283477</ArticleId><ArticleId IdType="pmc">5451599</ArticleId><ArticleId IdType="doi">10.1152/ajplung.00478.2016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Liu J, Zong R (2019) Triptolide protects against TGF-beta1-induced pulmonary fibrosis by regulating FAK/calpain signaling. Experimental therapeutic Med 18(6):4781–4789</Citation></Reference><Reference><Citation>Song D, Tang L, Wang L, Huang J, Zeng T, Fang H, Wang X (2020) Roles of TGFbeta1 in the expression of phosphoinositide 3-kinase isoform genes and sensitivity and response of lung telocytes to PI3K inhibitors. Cell Biol Toxicol 36(1):51–64</Citation><ArticleIdList><ArticleId IdType="pubmed">31522336</ArticleId><ArticleId IdType="doi">10.1007/s10565-019-09487-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JM, Han HJ (2011) L-threonine regulates G1/S phase transition of mouse embryonic stem cells via PI3K/Akt, MAPKs, and mTORC pathways. J Biol Chem 286(27):23667–23678</Citation><ArticleIdList><ArticleId IdType="pubmed">21550972</ArticleId><ArticleId IdType="pmc">3129147</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.216283</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabnam S, Pal A (2019) Relevance of Erk1/2-PI3K/Akt signaling pathway in CEES-induced oxidative stress regulates inflammation and apoptosis in keratinocytes. Cell Biol Toxicol 35(6):541–564</Citation><ArticleIdList><ArticleId IdType="pubmed">30805762</ArticleId><ArticleId IdType="doi">10.1007/s10565-019-09467-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayllon J, Garcia-Sastre A, Hale BG (2012) Influenza A viruses and PI3K: are there time, place and manner restrictions? Virulence 3(4):411–414</Citation><ArticleIdList><ArticleId IdType="pubmed">22722241</ArticleId><ArticleId IdType="pmc">3478246</ArticleId><ArticleId IdType="doi">10.4161/viru.20932</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu H, Mallya S, Nguyen P, Mai A, Jackson LV, Winkler DG, DiNitto JP, Brophy EE, McGovern K, Kutok JL et al (2017) The Selective Phosphoinoside-3-Kinase p110delta Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. Front Immunol 8:747</Citation><ArticleIdList><ArticleId IdType="pubmed">28713374</ArticleId><ArticleId IdType="pmc">5491903</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2017.00747</ArticleId></ArticleIdList></Reference><Reference><Citation>Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (2017) The PI3K Pathway in Human Disease. Cell 170(4):605–635</Citation><ArticleIdList><ArticleId IdType="pubmed">28802037</ArticleId><ArticleId IdType="pmc">5726441</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2017.07.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA (2015) Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways. Cancer Lett 360(2):134–140</Citation><ArticleIdList><ArticleId IdType="pubmed">25659819</ArticleId><ArticleId IdType="pmc">4415112</ArticleId><ArticleId IdType="doi">10.1016/j.canlet.2015.01.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lai Y, Wang Y, Liu N, Zhang F, Xu P (2016) 1, 8-Cineol Protect Against Influenza-Virus-Induced Pneumonia in Mice. Inflammation 39(4):1582–1593</Citation><ArticleIdList><ArticleId IdType="pubmed">27351430</ArticleId><ArticleId IdType="doi">10.1007/s10753-016-0394-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Davel LE, Jasnis MA, de la Torre E, Gotoh T, Diament M, Magenta G, Sacerdote de Lustig E, Sales ME (2002) Arginine metabolic pathways involved in the modulation of tumor-induced angiogenesis by macrophages. FEBS Lett 532(1–2):216–220</Citation><ArticleIdList><ArticleId IdType="pubmed">12459493</ArticleId><ArticleId IdType="doi">10.1016/S0014-5793(02)03682-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmi H, Kusano G, Ishida N (1980) Selective inhibition of nucleoside transport into mouse lymphoma L-5178Y cells by cimicfugoside. J Pharmacobiodyn 3(12):636–642</Citation><ArticleIdList><ArticleId IdType="pubmed">7277178</ArticleId><ArticleId IdType="doi">10.1248/bpb1978.3.636</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>